欧洲委员会将营销许可授予Vabomere

2018-11-28 MedSci MedSci原创

Melinta是一家开发新型抗生素以治疗严重细菌感染的制药公司,Melinta近日宣布欧盟委员会已经批准其Vabomere(Meropenem/vaborbactam)用于治疗复杂的腹腔内(cIAI)、尿路感染(cUTI)、医院获得性肺炎、感染相关的菌血症以及好氧革兰氏阴性菌引起的感染的成人患者。Vabomere在所有欧盟(EU)成员国以及挪威、冰岛和列支敦士登均获得了营销许可。

Melinta是一家开发新型抗生素以治疗严重细菌感染的制药公司,Melinta近日宣布欧盟委员会已经批准其VabomereMeropenem/vaborbactam)用于治疗复杂的腹腔内(cIAI)、尿路感染cUTI)、医院获得性肺炎、感染相关的菌血症以及好氧革兰氏阴性菌引起的感染的成人患者。Vabomere在所有欧盟(EU)成员国以及挪威、冰岛和列支敦士登均获得了营销许可。

Melinta的首席执行官兼董事John H. Johnson说:越来越多的耐药性肠杆菌科已经对全球患者构成了重大威胁。随着欧洲委员会对Vabomere的授权,预计Vabomere能够杀灭这种危及生命的病原体。这项批准源自于欧洲药品管理局(EMA)的人用药品委员会(CHMP)于20189月发布的积极意见,该意见则基于TANGO临床计划的数据。TANGO-1是一项III期、多中心、随机、双盲、双模拟研究,评估了Vabomere与哌拉西林-他唑巴坦治疗成人cUTI(包括急性肾盂肾炎)的有效性、安全性和耐受性。TANGO-2则是一项多中心、随机、开放标签的临床试验,评估了Vabomere与碳青霉烯类在有效性和安全性方面的差异。


原始出处:

http://www.firstwordpharma.com/node/1607240#axzz5Y7c6A8OV

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (3)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2019416, encodeId=8c412019416fd, content=<a href='/topic/show?id=fb11630689a' target=_blank style='color:#2F92EE;'>#欧洲委员会#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63068, encryptionId=fb11630689a, topicName=欧洲委员会)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83erCiat0j36p5MejdM9yCLtcVcY8WS5VIKuCMqXFNs56U6iacZib5CJvh6mVxGERicM6ZAkl91jMgpcDrw/132, createdBy=37622500012, createdName=ms2999106592497887, createdTime=Fri Mar 15 09:37:00 CST 2019, time=2019-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1339143, encodeId=bf1a1339143e3, content=<a href='/topic/show?id=447663054f5' target=_blank style='color:#2F92EE;'>#欧洲#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63054, encryptionId=447663054f5, topicName=欧洲)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Fri Nov 30 12:37:00 CST 2018, time=2018-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1598018, encodeId=23be15980181d, content=<a href='/topic/show?id=6c6f1e62c5' target=_blank style='color:#2F92EE;'>#ABO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1762, encryptionId=6c6f1e62c5, topicName=ABO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b6c918580135, createdName=闆锋旦, createdTime=Fri Nov 30 12:37:00 CST 2018, time=2018-11-30, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=2019416, encodeId=8c412019416fd, content=<a href='/topic/show?id=fb11630689a' target=_blank style='color:#2F92EE;'>#欧洲委员会#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63068, encryptionId=fb11630689a, topicName=欧洲委员会)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83erCiat0j36p5MejdM9yCLtcVcY8WS5VIKuCMqXFNs56U6iacZib5CJvh6mVxGERicM6ZAkl91jMgpcDrw/132, createdBy=37622500012, createdName=ms2999106592497887, createdTime=Fri Mar 15 09:37:00 CST 2019, time=2019-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1339143, encodeId=bf1a1339143e3, content=<a href='/topic/show?id=447663054f5' target=_blank style='color:#2F92EE;'>#欧洲#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63054, encryptionId=447663054f5, topicName=欧洲)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Fri Nov 30 12:37:00 CST 2018, time=2018-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1598018, encodeId=23be15980181d, content=<a href='/topic/show?id=6c6f1e62c5' target=_blank style='color:#2F92EE;'>#ABO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1762, encryptionId=6c6f1e62c5, topicName=ABO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b6c918580135, createdName=闆锋旦, createdTime=Fri Nov 30 12:37:00 CST 2018, time=2018-11-30, status=1, ipAttribution=)]
    2018-11-30 zhouqu_8
  3. [GetPortalCommentsPageByObjectIdResponse(id=2019416, encodeId=8c412019416fd, content=<a href='/topic/show?id=fb11630689a' target=_blank style='color:#2F92EE;'>#欧洲委员会#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63068, encryptionId=fb11630689a, topicName=欧洲委员会)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83erCiat0j36p5MejdM9yCLtcVcY8WS5VIKuCMqXFNs56U6iacZib5CJvh6mVxGERicM6ZAkl91jMgpcDrw/132, createdBy=37622500012, createdName=ms2999106592497887, createdTime=Fri Mar 15 09:37:00 CST 2019, time=2019-03-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1339143, encodeId=bf1a1339143e3, content=<a href='/topic/show?id=447663054f5' target=_blank style='color:#2F92EE;'>#欧洲#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=63054, encryptionId=447663054f5, topicName=欧洲)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=zhouqu_8, createdTime=Fri Nov 30 12:37:00 CST 2018, time=2018-11-30, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1598018, encodeId=23be15980181d, content=<a href='/topic/show?id=6c6f1e62c5' target=_blank style='color:#2F92EE;'>#ABO#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=22, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=1762, encryptionId=6c6f1e62c5, topicName=ABO)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=b6c918580135, createdName=闆锋旦, createdTime=Fri Nov 30 12:37:00 CST 2018, time=2018-11-30, status=1, ipAttribution=)]
    2018-11-30 闆锋旦